Skip to main content
SpringerLink
Log in

Exfoliative Skin Diseases: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  • Chapter
  • First Online:
Essential Burn Care for Non-Burn Specialists

  • 285 Accesses

Abstract

Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS/TEN overlap syndrome represent a spectrum of rare, but life-threatening type IV hypersensitive reactions to medications or infections. The clinical diagnosis of SJS versus SJS/TEN overlap, versus TEN is based upon the severity or amount of skin desquamation. The loss of skin increases the risk of infection, sepsis, multiple organ dysfunction, and death. Mortality is related to the amount of skin desquamation, patient risk factors, and comorbidities. Management is primarily supportive care, but specialized centers often use immunomodulating therapies to attempt to reduce the severity of the hypersensitivity reaction. Most important treatment options are to stop the causative agent, resuscitate, and promptly transfer to a specialized center able to treat SJS/TEN with multi-disciplinary specialists that can effectively treat the acute syndrome and mitigate long-term consequences.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34:1235–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Richard EB, Hamer D, Musso MW, Short T, O’Neal HR Jr. Variability in management of patients with SJS/TEN: a survey of burn unit directors. J Burn Care Res. 2018;39:585–92.

    Article  PubMed  Google Scholar 

  3. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139:683–93.

    Article  CAS  PubMed  Google Scholar 

  4. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136:1387–97.

    Article  CAS  PubMed  Google Scholar 

  5. Greenhalgh DG. Management of burns. N Engl J Med. 2019;380:2349–59.

    Article  PubMed  Google Scholar 

  6. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.

    Article  CAS  PubMed  Google Scholar 

  7. Noe MH, Rosenbach M, Hubbard RA, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol. 2019;155:448–54.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Carmichael H, Wiktor AJ, McIntyre RC, Lambert Wagner A, Velopulos CG. Regional disparities in access to verified burn center care in the United States. J Trauma Acute Care Surg. 2019;87:111–6.

    Article  PubMed  Google Scholar 

  9. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54:147–76.

    Article  CAS  PubMed  Google Scholar 

  10. Oakley AM, Krishnamurthy K. Stevens Johnson syndrome. Treasure Island: StatPearls; 2020.

    Google Scholar 

  11. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43:758–66.

    Article  CAS  PubMed  Google Scholar 

  12. Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin Dermatol. 2020;38:607–12.

    Article  PubMed  Google Scholar 

  13. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58:33–40.

    Article  PubMed  Google Scholar 

  14. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197–204.

    Article  CAS  PubMed  Google Scholar 

  15. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–30.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia—report of two cases in children. Am J Dis Child. 1922;24:526–33.

    Article  Google Scholar 

  17. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–6.

    Article  CAS  PubMed  Google Scholar 

  18. Lyell A. Toxic epidermal necrolysis—an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355–61.

    Article  CAS  PubMed  Google Scholar 

  19. Koh HK, Fook-Chong S, Lee HY. Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis. JAMA Dermatol. 2020;156(12):1294–9.

    Article  PubMed  Google Scholar 

  20. Schneider JA, Cohen PR. Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2017;77:e117.

    Article  PubMed  Google Scholar 

  21. Tocco-Tussardi I, Huss F, Presman B. Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. J Cutan Pathol. 2017;44:420–32.

    Article  PubMed  Google Scholar 

  22. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87–96.

    Article  CAS  PubMed  Google Scholar 

  23. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323–7.

    Article  CAS  PubMed  Google Scholar 

  24. Charlton OA, Harris V, Phan K, Mewton E, Jackson C, Cooper A. Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle). 2020;9:426–39.

    Article  PubMed  Google Scholar 

  25. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Curtis JA, Christensen LC, Paine AR, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis treatments: an internet survey. J Am Acad Dermatol. 2016;74:379–80.

    Article  PubMed  Google Scholar 

  27. McCullough M, Burg M, Lin E, Peng D, Garner W. Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience. Burns. 2017;43:200–5.

    Article  CAS  PubMed  Google Scholar 

  28. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–3.

    Article  CAS  PubMed  Google Scholar 

  29. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473–8.

    Article  CAS  PubMed  Google Scholar 

  30. Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153:514–22.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA

    Felicia N. Williams

  2. North Carolina Jaycee Burn Center, Chapel Hill, NC, USA

    Felicia N. Williams

  3. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA

    Jong O. Lee

  4. Shriners Children’s Texas, Galveston, TX, USA

    Jong O. Lee

Authors
  1. Felicia N. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jong O. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felicia N. Williams .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA

    Jong O. Lee

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Williams, F.N., Lee, J.O. (2023). Exfoliative Skin Diseases: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Lee, J.O. (eds) Essential Burn Care for Non-Burn Specialists. Springer, Cham. https://doi.org/10.1007/978-3-031-28898-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-28898-2_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-28897-5

  • Online ISBN: 978-3-031-28898-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation